. In particular, the following mutations have been discovered: missense mutations (19Lys>Glu, 134Arg>Lys, 128Leu>Pro, 176 Gly>Asp, 216Arg> His, 307Asn>Ile, 505Ala>Val, 513Arg>His, 744 Pro>Ser, 776Arg>His), nonsense mutations (133Cys>Stop, 378Lys>Stop, 460Glu>Stop, 597Trp>Stop), a codon deletion (212Lys del) and insertion (320Asn ins), and a single nucleotide insertion (565Gly insG), deletion (Exon 17+1Gdel) or substitution (Intron F -15T>G, Intron F -14T>G) (9, (13) (14) (15) (16) (17) . The human PLG gene is located on chromosome 6 and spans 52.5 kb in the q26 band with a coding region containing 19 exons and 18 introns (18, 19) . Because of its ancestral origin, the human PLG gene is highly homologous with genes belonging to the plasminogen-apo(a) gene family, which is composed of five genes (PLG, apolipoprotein(a), endothelial growth factor, PLG-related genes A and B) located on chromosome 6 (20) (21) (22) (23) (24) (25) . Moreover, some genes with unknown function, as well as a number of plasminogen-like genes (PLGL), located on the 11p-11q band of chromosome 2 and characterized by a marked homology with the human PLG coding region, have also been reported in the literature (26) . This article describes a gene co-amplification mimicking a 14bp deletion mutation in PLG gene exon 5 and various nucleotide exchanges belonging to a series of genes strictly homologous to PLG.
MATERIALS AND METHODS

Patients
Two patients affected with ligneous conjunctivitis and their available family members were investigated. The cases have already been described elsewhere (17) . The patients were observed at the Thrombotic and Hemorrhagic Diseases Center, Department of Medical and Surgical Sciences, Padua University. Informed consent according to the Helsinki Declaration was obtained from each patient before their inclusion in the study.
Blood Samples and Assays
Blood samples were collected after overnight fasting and after 15 minutes supine rest, without stasis, between 8:00 and 10:00 AM. Eighteen milliliters of whole blood were anticoagulated with 2 mL 0.13M Na-citrate. The samples were centrifuged at 3000 rpm for 15 minutes at 4°C and the separated plasma was stored at -20°C. For DNA analysis, the buffy coat was also stored at -20°C.
Plasminogen antigen (PLG:Ag) levels were assayed with Laurell's immunoelectrophoresis method using 1% agarose gel in Na barbital buffer, pH 8.6, containing 1% anti-plasminogen antiserum (Behringwerke, Marburg, Germany) (27) . Plasminogen activity (PLG:act) levels were assayed by a chromogenic method using streptokinase as activator (Behrichrom PL, Dade-Behring, Marburg, Germany) (28) .
Plasminogen Gene Mutation Analysis
Genomic DNA was extracted from peripheral white blood cells using the standard method.
The polymerase chain reaction (PCR) was used to amplify the exons and the intron-exon boundaries of the PLG gene. Exon-specific primer pairs were used (Life-Technologies, S. Giuliano Milanese, MI, Italy), as previously published (29) . The reaction was obtained in 50 µL total volume, using 6 µL of extracted DNA and 4 U Taq DNA Polymerase (Promega, Italy); the annealing temperature ranged between 55°C and 71°C, depending on the primer pair used. The PCR products were run on a 2% agarose gel stained with an ethidium bromide solution.
When the presence of a co-amplification product was suspected, a 3-hour and 30-minute electrophoretic run on a 3% NuSieve 3:1 agarose gel was performed.
Single-Strand Conformation Polymorphism Analysis of PLG Gene
To screen for plasminogen gene mutation, we used the single-strand conformation polymorphism (SSCP) analysis. For each exon, 10 µL of the PCR product were treated with a denaturing solution (formamide, xylene cyanol, bromophenol blue and 0.5M EDTA, pH 8) for 10 minutes at 98°C. Twenty microliters of denatured DNA were electrophoresed in a non-denaturing 5% polyacrylamide gel containing 5% glycerol in a 0.5X TBE buffer at room temperature for 90 minutes. DNA strands of both patients and the healthy control were detected with 0.1% silver nitrate staining.
DNA Cycle Sequencing
The amplicons were purified from agarose gel using an agarose gel DNA extraction kit (Roche Diagnostics GmbH, Mannheim, Germany). For each exon, PCR cycle sequencing was done in a master mix containing the ABI PRISM™ Big Dye Terminator with AmpliTaq DNA Polymerase FS (Applied Biosystems, Foster City, CA, USA). The forward and reverse primers were the same as those used in the first PCR reaction in a final 10 µL reaction volume. The automated sequence reaction was performed in an ABI PRISM™ 310 DNA Sequence Analyzer (Perkin Elmer, Foster City, CA, USA) and the products were analyzed with the Sequencing Analysis 3.0 software (Perkin Elmer, Foster City, CA, USA). Each sequence was finally compared with those of the human PLG gene available in the NCBI gene bank (NCBI Blast).
Numbering of nucleotides was made according to Forsgren and colleagues (18) .
PstI Restriction Analysis of Exon 5
Twenty microliters of the PLG exon 5 PCR product were digested with 20 U of the PstI restriction enzyme (BioLabs Inc., New England, USA), which recognizes the CTGCA M G cleavage site within this amplicon, in a PCR thermal cycler at 37°C for approximately 3 hours. The reaction product was run on a silver stained polyacrylamide gel.
RESULTS
In both probands, the plasma PLG:Ag and PLG:act levels were notably lower than normal (15% and 15.8% in patient 1; 25.5% and 29.7% in patient 2) and compatible with moderate hypoplasminogenemia (17) .
SSCP analysis of the exon 5 amplicon at an annealing temperature of 59°C unexpectedly showed 6 single-stranded DNA bands in patients with ligneous conjunctivitis and in the healthy control with normal PLG levels (Fig. 1 ). The first sequence analysis of the PLG exon 5 PCR product demonstrated a heterozygous 14 bp deletion (del523-536) disrupting the reading frame and leading to a TGA stop codon 40 bp downstream of the deletion site in both patients (patient 1, Fig. 2 ) and in the normal controls. PstI restriction analysis of the same PCR product showed a four-band pattern corresponding to the digested product (90 bp and 130 bp bands) and two uncleaved amplicons (206 bp and 240 bp bands) ( Fig. 3) .
After a 3-hour and 30-minute electrophoretic run on NuSieve agarose gel, a three-band pattern of the exon 5 PCR product (234, 220 and 206 bp) was detected ( Fig. 4, panel A) . The automated sequencing of the 220-bp band coincided with the published PLG exon 5 sequence ( Fig. 4, panel  B) , while the sequence of the 206-bp band disclosed the 14-bp deletion and three other nucleotide exchanges corresponding to 551C>G, 587A>C and 612T>C in the PLG cDNA ( Fig. 4,  panel B ). This DNA strand had a 95% similarity with PLG gene exon 5 and proved identical to a co-amplified gene tract located on chromosome 2 (AC093616.5, NT_022184.13), as confirmed by nucleotide BLAST alignment analysis.
To eliminate this pseudogene, PCR of the PLG exon 5 was carried out at increasing annealing temperatures and a single 220-bp band was obtained on the long run NuSieve gel electrophoresis at 71°C. The SSCP analysis of the 71°C annealing temperature PCR product showed two single-stranded and one double-stranded DNA bands both in patients and in controls ( Fig. 1 ). Sequence analysis of this PCR product in the two patients with ligneous conjunctivitis and in the normal control confirmed that it was identical to the PLG gene exon 5 ( Fig. 5 ) and no mutations were observed. Moreover, the PstI restriction analysis showed only a two-band pattern corresponding to the digested product (90-bp and 130-bp bands).
Characterizing all the other PLG genes exons led to the detection of a number of pseudo-mutations that mimicked heterozygous defects, but were due to co-amplified products of plasminogen-apo(a) gene family and pseudogenes, as shown in Table 1 .
As previously reported, two significant PLG gene mutations were recognized in our patients with ligneous conjunctivitis, namely the 19Lys>Glu mutation and the intron F-14T>G substitution, as well as six other nucleotide exchanges in both exons and introns (17) .
DISCUSSION
PLG is the key proenzyme of the fibrinolytic system, which is involved in dissolving fibrin deposits and in several extravascular proteolytic processes. Inherited type I PLG deficiency with little or no PLG can cause ligneous conjunctivitis, a rare disabling disease transmitted as an autosomal recessive trait. Molecular studies on the PLG gene in patients with ligneous conjunctivitis have demonstrated several mutations in both exons and introns of PLG coding region. On clinical grounds, identifying PLG gene mutations is useful to complete the diagnosis both in patients suffering from ligneous conjunctivitis and in heterozygous carriers of the defect. It may also be used for prenatal diagnosis in selected cases, as reported recently (30) . The genetic characterization of PLG defects is often difficult, however, because of the PLG gene's marked homology with other genes belonging to the plasminogen-apo(a) family and with pseudogenes located in different chromosomal regions. In fact, these homologous genes can easily be co-amplified in PCR analysis by the primer pairs used to study the PLG gene, thus posing a considerable challenge in detecting mutations within the PLG coding regions during the genetic analysis of patients with ligneous conjunctivitis.
This was the problem we encountered while studying our two patients with ligneous conjunctivitis. We found it particularly interesting to investigate a suspected heterozygous 14-bp deletion mutation in exon 5 of PLG gene (del 523-536) leading to a TGA stop codon 40 bp downstream from the deletion site. Because the mutation is seen in normal controls too, it was suspected of being another gene co-amplification. Because a few mutations in PLG exon 5 have already been described in patients with ligneous conjunctivitis (15, 16) , we had to obtain a pure PCR product for a correct sequence analysis of exon 5 in our patients. The only useful approach was to considerably increase the annealing temperature-up to 71°C-in the PCR reaction: this enabled us to obtain only a 220 bp band and, using the NCBI nucleotide BLAST alignment program, its sequence analysis confirmed the identity with PLG gene exon 5. The potential occurrence of mutations in PLG exon 5 was thus ruled out in both of our patients. By contrast, the co-amplified product carrying the 14-bp deletion as well as three other point mutations was recognized as a nucleotide strand belonging to a pseudogene located on chromosome 2. This paper is also the first to describe a number of false mutations due to co-amplified PLGlike genes and pseudogenes, seen while analyzing the other PLG gene exons and boundary introns. Identifying and eliminating these co-amplified homologous sequences enabled us to analyze the PLG gene sequence correctly (without any false-positive results) and to recognize the true genetic defects affecting our patients, as recently reported. Nucleotide numbering on PLG cDNA are reported according to Forsgren and colleagues (18) .
